Log In Get Started
Press Releases August 27, 2026 09:01 AM

GRI Bio Featured in "Why Now" On-Demand Video Webcast

GRI Bio featured in 'Why Now' on-demand video webcast to highlight its innovative therapies.

By Marcus Reed
Share
Twitter Reddit Facebook LinkedIn
GRI

GRI Bio, a biotechnology company listed on NASDAQ, announced its feature in the 'Why Now' on-demand video webcast, showcasing its work on developing therapies for inflammatory, fibrotic, and autoimmune diseases.

GRI Bio Featured in "Why Now" On-Demand Video Webcast
GRI
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • GRI Bio is highlighted in a webcast focused on innovative biotechnology developments.
  • The company is advancing therapies targeting inflammatory, fibrotic, and autoimmune disorders.
  • The webcast aims to increase awareness and visibility of GRI Bio's therapeutic pipeline.

Video webcast now available here

LA JOLLA, CA, Aug. 27, 2026 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company developing innovative therapies for inflammatory, fibrotic and autoimmune diseases, today announced that it is featured in a

Risks

  • Market and clinical development risks inherent in biotechnology and pharmaceutical industries.
  • Uncertainty over how much the webcast exposure will translate into investor interest or new partnerships.
  • The competitive landscape for therapies in inflammatory and autoimmune diseases is intense and evolving.

More from Press Releases

SEALSQ Majority-Owned Wecan Group Partners with SwissBorg to List the WECAN Token Aug 27, 2026 T1 Giga Arctic Approved for Data Center Development Aug 27, 2026 Myriad Genetics to Present at 2026 Wells Fargo Healthcare Conference Aug 27, 2026 Philips and Imricor launch cardiac interventional MR lab solution, expanding longstanding collaboration Aug 27, 2026 Moleculin CEO, Walter Klemp, Participates in the Virtual Investor “Why Now” On-Demand Conference Aug 27, 2026